Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs IRMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

IRMD Overall Winner 6-Pillar Tally: AHCO 2 – 4 IRMD Matrix Metrics: AHCO 4 – 6 IRMD

As of Nov 20, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas IRMD carries 42.0/100 (HOLD) at $81.02 (33.2x Forward P/E, 32.3% operating margin).

  • Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IRMD 42.0/100 HOLD), IRMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (32.3% vs. 3.8% operating margin) and revenue trajectory (+14.2% vs. +10.9% YoY).
  • Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile IRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs IRMD
AHCO NASDAQ
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
IRMD NASDAQ Head-to-Head Winner
iRadimed Corporation
Surgical & Medical Instruments & Apparatus
$81.02
-0.3% 1D
Market Cap $1.0B
TTM Revenue $89M
Forward P/E 33.2x
Beta / 30D Vol 0.67β · 54% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 31.0 Fund 48.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.0%), weak momentum, RSI 39
RSI-14: 39.4 · SMA20: $83.98 · SMA50: $85.24

6-Pillar Scorecard Institutional Category Breakdown (AHCO 2 – 4 IRMD)

Columns: Metric · AHCO · IRMD
1. Valuation Multiples AHCO
Forward P/E 7.8x 33.2x
Trailing P/E 7.8x 43.5x
PEG Ratio N/M 4.46x
EV / Revenue 0.9x 11.6x
2. Growth & Scale IRMD
Revenue Growth (YoY) +10.9% +14.2%
Earnings Growth (YoY) +6.7% +18.3%
TTM Revenue (USD) $3.44B $89M
Market Cap $989.8M $1.0B
3. Profitability & Quality IRMD
Gross Margin 18.2% 75.5%
Operating Margin 3.8% 32.3%
Net Profit Margin -11.8% 26.9%
Return on Equity (ROE) -28.4% 23.4%
4. Balance Sheet & Cash Flow IRMD
Cash Generation (TTM) $82M $26M
Cash Flow Margin 2.4% 28.7%
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $8.32 Book/Sh · 23.4% ROE
Dividend Yield None (0.00%) 0.97%
5. Options & Positioning AHCO
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 66.9% (12th %ile) 37.2% (6th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat IRMD
OpEx & R&D Intensity 14.4% of Rev ($495M) 43.2% of Rev ($39M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (4) vs IRMD (6)
Institutional Metric AHCO IRMD Criterion Row Edge
Market Capitalization
Scale
$989.8M $1.0B Larger Scale IRMD
Trailing P/E Ratio
Valuation
7.8x 43.5x Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x 33.2x Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+10.9% +14.2% Higher Growth IRMD
Operating Margin (TTM)
Profitability
3.8% 32.3% Higher Margin IRMD
Net Profit Margin
Profitability
-11.8% 26.9% Higher Margin IRMD
Return on Equity (ROE)
Capital Efficiency
-28.4% 23.4% Higher ROE IRMD
52-Week Range Position
Momentum
24% ($5–$13) 15% ($76–$108) Stronger Trend AHCO
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol 0.67β · 54% Vol Lower Realized Risk IRMD
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 42.0 / 100 (HOLD) Higher Composite AHCO
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $89M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 75.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev 4.46x PEG · 11.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) $26M ($8.32 Book/Sh · 23.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +24.24 pp
AHCO: +16.69% · IRMD: -7.55%
3M Horizon AHCO +34.96 pp
AHCO: +27.89% · IRMD: -7.07%
6M Horizon IRMD +19.07 pp
AHCO: -31.1% · IRMD: -12.03%
1Y Horizon IRMD +14.45 pp
AHCO: -20.88% · IRMD: -6.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AHCO Revenue IRMD Revenue AHCO Op. Margin IRMD Op. Margin Margin Leader
FY2018 $350M $30M 9.0% 19.7% IRMD
FY2019 $530M $40M 5.5% 22.5% IRMD
FY2020 $1.06B $30M 6.8% -2.4% AHCO
FY2021 $2.45B $40M 9.2% 23.5% IRMD
FY2022 $2.97B $50M 6.4% 29.3% IRMD
FY2023 $3.20B $70M -18.7% 30.6% IRMD
FY2024 $3.26B $70M 8.1% 30.0% IRMD
FY2025 $3.24B $80M 2.8% 31.2% IRMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IRMD CONSOLIDATION
98d in phase · OBV DISTRIBUTION
Current IV 37.2%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact IRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
IRMD Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $1.0B market capitalization and 32.3% operating margin.
OpEx & R&D Reinvestment 43.2% of Rev ($39M)
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs IRMD Key Questions & Quantitative Answers

As of Nov 20, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas IRMD carries 42.0/100 (HOLD) at $81.02 (33.2x Forward P/E, 32.3% operating margin). Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IRMD 42.0/100 HOLD), IRMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (32.3% vs. 3.8% operating margin) and revenue trajectory (+14.2% vs. +10.9% YoY). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile IRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRMD leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with IRMD at +14.2% YoY revenue growth and +18.3% YoY earnings growth on $89M TTM revenue (75.5% gross margin, 32.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while IRMD shifted +166.7%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 43.2% of Rev ($39M) (0 disclosures) for IRMD.

AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas IRMD trades at 33.2x Forward P/E, 43.5x Trailing P/E, 4.46x PEG, and 11.6x EV/Revenue (28.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus IRMD (23.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, IRMD carries 37.2% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.67β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.